Payers Are Preparing For Coming Companion Diagnostics, Medco Notes
Executive Summary
Companion diagnostics and biomarkers were the watchwords of the recent ASCO meeting as the cancer community braces for a sea change in treatment. But as more targeted drugs and companion diagnostics make it through the clinical and regulatory arenas, payers will have to grapple with managing the more complex real-world use of these therapies.
You may also be interested in...
Personalized Medicine Takes Aim At Common Diseases
While oncology steals the limelight, some firms are harnessing the technologies and R&D strategies of precision medicine to develop combination drug/diagnostic products for large-population, non-oncology diseases.
With Personalized Medicine, Payers Want A Role In Early Development
With the development of targeted therapies and companion diagnostics increasing, AmerisourceBergen Consulting’s president advises pharma industry to bring payers in around Phase II to ensure trials give them data they need to cover drugs and diagnostics.
Quality Of Biomarkers Questioned Again; Lancet Report Calls For Better Evidence
As personalized medicine shifts from theory to practice, concerns are mounting about whether the evidence behind many biomarkers is sufficient to make pharmacogenomic testing worthwhile – suggesting sponsors should pay careful attention to providing evidence to support use of companion diagnostics.